ProfileGDS5678 / 1427026_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 98% 99% 73% 85% 60% 52% 70% 76% 61% 62% 78% 71% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7469962
GSM967853U87-EV human glioblastoma xenograft - Control 210.684998
GSM967854U87-EV human glioblastoma xenograft - Control 311.304799
GSM967855U87-EV human glioblastoma xenograft - Control 44.855773
GSM967856U87-EV human glioblastoma xenograft - Control 56.4062885
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6695860
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3546652
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3440670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0960376
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6201461
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6767362
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4491278
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.450571
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7813663